

State of Oklahoma

SoonerSelect SoonerCare

	ame:	Date o	of Birth:	Member ID#:		
		Dr	ug Informatio	n		
hysician	billing (HCPCS code:) Start Da	te:		
		Billing P	Provider Inform	mation		
Provider N	PI:		Provider	Name:		
Provider P	hone:			^E ax:		
		Presc	criber Informa	tion		
Prescriber NPI: Prescriber Phone:		Prescriber Name:				
		_ Prescrib	per Fax:	Specialty:		
			Criteria			
requirem			a [®] risk evaluation a	and mitigation strategy (REMS) p	program	
А. В.	ultiple Myeloma Is disease status relapsed o	r refractory? ist 4 lines of monoclonal a	prior therapy includ antibody? Yes I	ling an immunomodulatory agen No	t, a proteasome	
А. В.	ultiple Myeloma Is disease status relapsed o Has member received at lea inhibitor, and an anti-CD38 r Please list therapies member i. For the therapies listed, o regimen? Yes No	r refractory? ast 4 lines of monoclonal a er has tried a did the memb	prior therapy includ antibody? YesI and failed: ber undergo at leas			
А. В.	ultiple Myeloma Is disease status relapsed o Has member received at lea inhibitor, and an anti-CD38 r Please list therapies member i. For the therapies listed, o regimen? Yes No 1. If no, please list ther a. Was progressiv ii. Do the therapies listed in	r refractory? ast 4 lines of monoclonal a er has tried a did the memb rapies memb ve disease se clude inducti	prior therapy includ antibody? Yes and failed: ber undergo at leas ber received for less een after 1 cycle of ion with or without	No	ent for each	
A. B. C.	ultiple Myeloma Is disease status relapsed of Has member received at lea inhibitor, and an anti-CD38 m Please list therapies member i. For the therapies listed, of regimen? Yes No 1. If no, please list ther a. Was progressiv ii. Do the therapies listed in without maintenance ther Does the member have mea Please check all that apply: Urine M-protein ≥200 Serum M-protein ≥0.5	r refractory? ast 4 lines of monoclonal a er has tried a did the memb rapies memb ve disease se clude inducti rapy? Yes asurable dise mg/24hr 5g/dL	prior therapy includ antibody? Yes and failed: ber undergo at lease ber received for less een after 1 cycle of ion with or without No ease as evidenced Bone marrow pla Serum free light of	No st 2 consecutive cycles of treatme s than 2 consecutive cycles: each of these therapies? Yes	ent for each No cell transplant with o s No arrow cells ≥10mg/dL (100mg/	
A. B. C. D.	ultiple Myeloma Is disease status relapsed of Has member received at lea inhibitor, and an anti-CD38 m Please list therapies member i. For the therapies listed, of regimen? Yes No 1. If no, please list ther a. Was progressiv ii. Do the therapies listed in without maintenance ther Does the member have mea Please check all that apply: Urine M-protein ≥200 Serum M-protein ≥0.5	r refractory? ast 4 lines of monoclonal a er has tried a did the memb rapies memb ve disease se clude inducti rapy? Yes asurable dise mg/24hr 5g/dL tral nervous se	prior therapy includ antibody? Yes and failed: ber undergo at leas ber received for less een after 1 cycle of ion with or without No ease as evidenced Bone marrow pla Serum free light of system involvement	No at 2 consecutive cycles of treatme as than 2 consecutive cycles: autologous hematopoietic stem of by at least 1 of the following? Ye sma cells >30% of total bone matchain (FLC) assay: involved FLC at with multiple myeloma? Yes	 ent for each No cell transplant with o es No arrow cells ≥10mg/dL (100mg/ No	

requested clinical notes will result in processing delays.

Fax completed prior authorization request form to 888-601-8461 or submit Electronic Prior Authorization through CoverMyMeds® or SureScripts. All requested data must be provided. Incomplete forms or forms without the chart notes will be returned. Pharmacy Coverage Guidelines are available at AetnaBetterHealth.com/Oklahoma.

CONFIDENTIALITY NOTICE

This document, including any attachments, contains information which is confidential or privileged. If you are not the intended recipient, be aware that any disclosure, copying, distribution, or use of the contents of this information is prohibited. If you have received this document in error, please notify the sender immediately by telephone to arrange for the return of the transmitted documents or to verify their destruction.